Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01668849 · ClinicalTrials.gov registry record · Phase 1
Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer
A Phase 1 study, sponsored by University of Louisville.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01668849 is a Phase 1 study that has completed, run by University of Louisville. The registered enrollment target is 60 participants.
The verdict
NCT01668849, a Phase 1 study, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the ability of grape exosomes, given to the subject as grape powder, as an important anti-inflammatory agent to reduce the incidence of oral mucositis during radiation and chemotherapy treatment for head and neck tumors.
Interventions
- DIETARY_SUPPLEMENT Grape extract
- DRUG Lortab, Fentanyl patch, mouthwash
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-08-02 |
| Est. Completion | 2022-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01668849
The ClinicalTrials.gov registry entry for NCT01668849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Grape extract is the first listed.
NCT01668849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01668849 about?
NCT01668849 is a clinical study titled "Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer". This study will evaluate the ability of grape exosomes, given to the subject as grape powder, as an important anti-inflammatory agent to reduce the incidence of oral mucositis during radiation and chemotherapy treatment for head and neck tumors.
What is the current status of trial NCT01668849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2012-08-02. Estimated completion is 2022-06-03.
What interventions are being tested in trial NCT01668849?
The interventions under investigation include: Grape extract (DIETARY_SUPPLEMENT), Lortab, Fentanyl patch, mouthwash (DRUG).
Who is sponsoring clinical trial NCT01668849?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.